OrbusNeich Receives “Health Partnership Awards 2025 – Outstanding Innovative Medical Device Solutions”

(Hong Kong, March 27, 2026) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, has won the “Outstanding Innovative Medical Device Solution” in the Health Innovation category at the “Health Partnership Awards 2025” organized by ET Net, a leading Hong Kong financial information and media platform.

This accolade underscores OrbusNeich’s excellence in developing innovative solutions for the treatment of vascular disease, reflecting the Group’s ongoing commitment to delivering comprehensive medical solutions, supporting clinicians treating coronary and peripheral vascular disease, and contributing to the advancement of global public health.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Building on 25 years of expertise, OrbusNeich continues to advance product innovation and quality through dedicated local teams and a global sales network spanning over 70 countries and regions, ensuring our interventional solutions benefit vascular disease patients worldwide. We have furthered our strategy by expanding this extensive network, forging key collaborations, and strengthening our portfolio with our proprietary products, and eucatech AG products, as well as third-party offerings.”

Organized by the Hong Kong financial information platform ET Net, this year’s Health Partnership Awards featured the theme “Refine Life through Wellness Intelligence.” The awards aim to raise public awareness of healthy living and quality wealth management, while recognizing individuals and organizations that have made outstanding contributions to healthcare, financial products, and society—particularly in promoting healthy lifestyles and enhancing community well‑being.

Ms. Maggie Lau, Corporate Communications Manager of OrbusNeich, receives the Health Partnership Awards 2025 on behalf of the Group.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.